Accolade

Accolade, Inc. engages in the provision of personalized health and benefits solutions. Its products include Accolade Total Benefits, which is designed for employers with low employee adoption of healthcare and benefits programs, Accolade Total Care, which focuses on influencing the actual interactions between employees and providers, and are also interested in care management services, and Accolade Total Health and Benefits, which offers a full suite of solutions. The company was founded by Thomas K. Spann, J. Michael Cline, and Sudhir Steven Singh in 2007 and is headquartered in Seattle, WA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Accolade reports strong Q4 performance, faces market challenges ahead

Accolade's transformation into a personalized healthcare company has shown strong growth and improved financial performance. The company faces challenges related to operational excellence, market strategy, and the impact of industry decisions. However, opportunities lie in leveraging technology for healthcare and the upcoming Capital Markets Day to showcase growth prospects.

Accolade exceeds Q3 revenue guidance, eyes profitability by fiscal '25

Accolade's Q3 earnings call highlighted strong performance, diverse customer relationships, and growth opportunities in government business and virtual care. The company aims to achieve profitability by fiscal '25 through strategic investments and operational improvements, leveraging its competitive advantage in delivering ROI and performance guarantees.

Accolade reports robust Q4 performance, eyes tech-driven growth opportunities

Accolade's Q4 2023 Earnings Call highlighted strong financial performance, customer focus, and strategic initiatives. The company faces challenges in timing performance guarantees but sees opportunities in technology adoption and growth strategies.

Accolade surpasses Q1 expectations, eyes growth in healthcare partnerships

Accolade's Q1 performance exceeded expectations, with a focus on growth drivers and streamlining decision-making. Despite challenges in the government business, the company is optimistic about future growth opportunities and customer acquisition. Improved guidance and a strong pipeline indicate a positive outlook for the year.

Accolade beats Q2 revenue targets, eyes profitability in fiscal '25

Accolade exceeded revenue and EBITDA expectations in Q2, driven by strong customer additions and unique service offerings. Despite challenges from drug impacts and contract disputes, the company maintains its full-year guidance and eyes profitability in fiscal '25.

Accolade excels in Q3, eyes automation for growth opportunities

Accolade's Q3 performance exceeded expectations, with a positive outlook for future revenue and EBITDA. Differentiation in services and technology integration drive operational excellence. Uncertainty around TRICARE contract and focus on automation and growth opportunities.

Accolade reports robust Q4 earnings, eyes sustainable growth in '25

Accolade's strong performance in Q4 2024 sets a positive trajectory for fiscal year '25, with a focus on sustainable growth and profitability. The company's strategic strengths in serving a large customer base, successful partnerships, and innovative offerings position it well for future opportunities despite challenges in meeting revenue guidance and addressing post-security breach concerns.

Accolade reports strong Q2 earnings, focuses on profitability and growth

Accolade's Q2 performance exceeded expectations, emphasizing profitability and member experience.
The company's strengths lie in revenue growth, cost management, and competitive wins.
Challenges include cost structure management and balancing growth with profitability.
Opportunities exist in enhancing member experience, expanding partnerships, and driving sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accolade, Inc. engages in the provision of technology-enabled health and benefits solutions. The company was founded by Thomas K. Spann and J. Michael Cline in January 2007 and is headquartered in Seattle, WA.

Health benefits technology company Accolade says it will provide access to mental health support, including on-demand virtual therapy, in partnership with mental health service Ginger. The partnership, announced Thursday morning, will include proactive outreach to participating Accolade members deemed at risk of mental health challenges, based on data analysis.

Accolade adds mental health support through Ginger partnership, citing growing crisis

SEATTLE, Sept.  01, 2020  (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, will participate in the virtual Morgan Stanley 18th Annual Healthcare Conference, including a fireside chat presentation on Monday, September 14, 2020 at 1:30 p.m. E.T. An audio webcast and related presentation materials will be available at ir.accolade.com.

Accolade to Participate in the Morgan Stanley 18th Annual Healthcare Conference

Accolade's (ACCD) CEO Rajeev Singh on Q1 2021 Results - Earnings Call Transcript

Seattle entrepreneur and former Concur president Raj Singh was back in the earnings hot seat Thursday afternoon as the CEO of Accolade, walking analysts and investors through the health benefits technology company’s first quarterly report since going public last month in a $1.

Health tech company Accolade boosts revenue 25% in first report since IPO, as COVID-19 roils industry

SEATTLE, Aug.  13, 2020  (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced financial results for the fiscal first quarter ended May 31, 2020.

Accolade Announces Results for Fiscal First Quarter 2021

SEATTLE, July  27, 2020  (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced that it will release fiscal first quarter 2021 financial results on Thursday, August 13, 2020, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. E.T. on the same day.

Accolade to Announce Fiscal First Quarter 2021 Financial Results

The Landmark Deal Will Include Geyser Peak, Atlas Peak, XYZin and Outlot WinesNapa, California--(Newsfile Corp. - July 23, 2020) -  Family owned-and-operated fine wine importer Quintessential will become the custodian of all U.S.

Quintessential Acquires U.S. Brands From Accolade Wines

SEATTLE, July 7, 2020 /PRNewswire/ -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced the closing of its initial public...

Accolade Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Accolade’s share price is up 38% since its initial public offering on Thursday, marking a successful debut for the health benefits management company at a time of unprecedented uncertainty in the industry, the economy and the broader world.

Accolade CEO Raj Singh on health tech company’s IPO, path to profits, and the pandemic’s ‘second hit’

Accolade - Interesting Tech And Healthcare Offering

Dun & Bradstreet Holdings

Lemonade

Three IPOs raised $2.3 billion this past week, led by Dun & Bradstreet's billion-dollar deal. All three IPOs upsized their deals and priced above the range.

U.S. IPO Weekly Recap: 3 IPOs Close Out The 2Q In Shortened Holiday Week

Despite today’s bucket of plus-and-minus economic data, stocks are heading higher in regular trading. And among the shares rising the most are today’s two venture-backed IPOs: Lemonade and Accolade.

Lemonade and Accolade open sharply higher as public markets rally

Health benefits platform Accolade made its initial public offering Thursday morning, pricing its stock at $22/share, above the expected range of $19 to $21, and raising $220 million at a valuation of $1.

News for Accolade Stock (ACCD)